Daphne Koller, Getty

Bris­tol My­er­s' Richard Har­g­reaves pays $70M to launch a neu­rode­gen­er­a­tion al­liance with a star play­er in the ma­chine learn­ing world

Bris­tol My­ers Squibb is turn­ing to one of the star up­starts in the ma­chine learn­ing world to go back to the draw­ing board and come up with the dis­ease mod­els need­ed to find drugs that can work against two of the tough­est tar­gets in the neu­ro world.

Daphne Koller’s well-fund­ed in­sitro is get­ting $70 mil­lion in cash and near-term mile­stones to use their ma­chine learn­ing plat­form to cre­ate in­duced pluripo­tent stem cell-de­rived dis­ease mod­els for ALS and fron­totem­po­ral de­men­tia.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

Cambridge, MA, USA